摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

8-(1,3-benzodioxol-5-yloxy)-1-methyl-4,5-dihydro-1H-thieno[3,4-g]indazole-6-carboxamide | 364760-98-5

中文名称
——
中文别名
——
英文名称
8-(1,3-benzodioxol-5-yloxy)-1-methyl-4,5-dihydro-1H-thieno[3,4-g]indazole-6-carboxamide
英文别名
4,5-dihydro-1-methyl-8-(3,4-methylenedioxyphenoxy)-1H-thieno[3,4-g]indazole-6-carboxamide;4,5-dihydro-8-(3,4-methylenedioxyphenoxy)-1-methyl-1H-thieno[3,4-g]indazole-6-carboxamide;8-(1,3-benzodioxol-5-yloxy)-1-methyl-4,5-dihydrothieno[3,4-g]indazole-6-carboxamide
8-(1,3-benzodioxol-5-yloxy)-1-methyl-4,5-dihydro-1H-thieno[3,4-g]indazole-6-carboxamide化学式
CAS
364760-98-5
化学式
C18H15N3O4S
mdl
——
分子量
369.401
InChiKey
MCJLWQSLECQQPQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    26
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    117
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    8-(1,3-benzodioxol-5-yloxy)-1-methyl-4,5-dihydro-1H-thieno[3,4-g]indazole-6-carboxamide乙酸乙酯碳酸氢钠氯化钠magnesium sulfateethyl acetate n-hexane 作用下, 以 三氟乙酸 为溶剂, 反应 3.0h, 以the title compound (1.45 g, 80%) was obtained as colorless needles的产率得到6-Cyano-4,5-dihydro-1-methyl-8-(3,4-methylenedioxyphenoxy)-1H-thieno[3,4-g]indazole
    参考文献:
    名称:
    Fused heterocyclic derivatives, their production and use
    摘要:
    本发明披露了新型的融合噻吩衍生物作为预防和治疗骨骼或关节疾病的药物,具有工业优势的制备方法以及新型的制备中间体。所述融合噻吩衍生物由通式(I)表示:其中R1为可选取代的碳氢化合物、杂环、磺酰基、磺酰基、羟基、硫醇或氨基基团;R2为氰基、甲酰基、硫代甲酰基等;环A为2中的任意一种(其中R3为氢或可选取代的碳氢化合物、杂环、羟基、氨基、磺酰基或酰基;R14为氢、卤素、可选取代的碳氢基团、可选取代的杂环基团等);环B代表可选取代的5-至7-成员的碳氢环。
    公开号:
    US20030158245A1
点击查看最新优质反应信息

文献信息

  • DIABETES THERAPEUTIC AGENT
    申请人:Oka Masahiro
    公开号:US20130184272A1
    公开(公告)日:2013-07-18
    The problem of the present invention is to provide a compound useful for the prophylaxis or treatment of diseases related to the control of the differentiation of muscle cell or adipocyte differentiation, such as diabetes, obesity, dyslipidemia, and having a superior efficacy. The present invention provides an agent for the prophylaxis or treatment of diabetes, obesity or dyslipidemia, containing a compound represented by the formula (I) wherein each symbol is as defined in the DESCRIPTION, or a salt thereof or a prodrug thereof.
    本发明的问题是提供一种化合物,可用于预防或治疗与肌肉细胞分化或脂肪细胞分化控制相关的疾病,如糖尿病、肥胖症、血脂异常等,并具有优越的疗效。本发明提供了一种用于预防或治疗糖尿病、肥胖症或血脂异常的药剂,该药剂含有由式(I)所表示的化合物,其中每个符号如在说明书中定义的,或其盐或前药。
  • Process for producing phospholipid-containing drug
    申请人:——
    公开号:US20030185878A1
    公开(公告)日:2003-10-02
    The present invention provides a pharmaceutical preparation which is safe, little irritate subjects and comprises a water-insoluble or hardly water-soluble drug at a high level, and a simple and convenient process for producing the preparation. A process for producing a pharmaceutical composition comprising a water-insoluble or hardly water-soluble drug coated with phospholipid, said process comprising mixing a solution containing the water-insoluble or hardly water-soluble drug and phospholipid in an organic solvent with an aqueous solvent, emulsifying the resultant mixture and removing the organic solvent from the emulsion thus obtained to form a phospholipid coating film on the surface of the water-insoluble or hardly water-soluble drug.
    本发明提供了一种制药制剂,该制剂安全、对受试者刺激小,并且包含高平的难溶于或几乎不溶于的药物,以及一种简单方便的制备过程。一种制备含有磷脂质包被的难溶于或几乎不溶于的药物的制药组合物的方法,该方法包括将含有难溶于或几乎不溶于的药物和磷脂质的溶液与有机溶剂混合后与溶液乳化,然后从所得乳液中去除有机溶剂,以在难溶于或几乎不溶于的药物表面形成磷脂质包被膜。
  • PROCESS FOR PRODUCING PHOSPHOLIPID-CONTAINING DRUGS
    申请人:Takeda Chemical Industries, Ltd.
    公开号:EP1293197A1
    公开(公告)日:2003-03-19
    The present invention provides a pharmaceutical preparation which is safe, little irritate subjects and comprises a water-insoluble or hardly water-soluble drug at a high level, and a simple and convenient process for producing the preparation. A process for producing a pharmaceutical composition comprising a water-insoluble or hardly water-soluble drug coated with phospholipid, said process comprising mixing a solution containing the water-insoluble or hardly water-soluble drug and phospholipid in an organic solvent with an aqueous solvent, emulsifying the resultant mixture and removing the organic solvent from the emulsion thus obtained to form a phospholipid coating film on the surface of the water-insoluble or hardly water-soluble drug.
    本发明提供了一种安全、对受试者刺激小、含有高浓度不溶性或难溶性药物的药物制剂,以及一种简单方便的制剂生产工艺。一种药物组合物的生产工艺,该药物组合物包括涂有磷脂不溶性或难溶性药物,所述工艺包括将有机溶剂中含有不溶性或难溶性药物和磷脂的溶液与溶剂混合,乳化所得混合物,并从所得乳液中除去有机溶剂,从而在不溶性或难溶性药物表面形成磷脂涂膜。
查看更多